U.S. markets closed

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0000-0.0200 (-1.96%)
At close: 4:00PM EDT

Adamis Pharmaceuticals Corporation

11682 El Camino Real
Suite 300
San Diego, CA 92130
United States
858 997 2400
http://www.adamispharmaceuticals.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees116

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard C. WilliamsIndependent Chairman & Consultant128kN/A1944
Dr. Dennis J. CarloPres, CEO & Director982.81kN/A1943
Mr. Robert O. HopkinsSr. VP of Fin., CFO & Sec.579.96kN/A1960
Mr. David J. MarguglioSr. VP, Chief Bus. Officer & DirectorN/AN/A1970
Dr. Ronald B. MossChief Medical Officer613.65kN/A1961
Mr. Howard C. BirndorfIndependent Director & Consultant64kN/A1951
Ms. Roshawn A. BluntIndependent Director & Consultant64kN/A1975
Ms. Karen K. DanielsVP of OperationsN/AN/A1953
Mr. David C. BenedictoPrincipal Accounting OfficerN/AN/A1961
Mr. Mark FlatherSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.

Corporate Governance

Adamis Pharmaceuticals Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.